Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12779/5304
Title: 3,5-dibenzoyl-4-(3-phenoxyphenyl)-1,4-dihydro-2,6-dimethylpyridine (DP7): a new multidrug resistance inhibitor devoid of effects on Langendorff-perfused rat heart.
Authors: Saponara, Simona
Ferrara, A
Gorelli, B
Shah, A
Kawase, M
Motohashi, N
Molnar, J
Sgaragli, GIAN PIETRO
Fusi, Fabio 
Issue Date: 2007
Project: None 
Journal: EUROPEAN JOURNAL OF PHARMACOLOGY
Abstract: 
Cardiac effects of 3,5-dibenzoyl-4-(3-phenoxyphenyl)-1,4-dihydro-2,6-dimethylpyridine (DP7), a novel multidrug resistance (MDR) inhibitor, in Langendorff-perfused rat heart have been investigated and compared to that of nifedipine. Nifedipine decreased concentration-dependently (IC50=8.89+/-1.09x10(-8) M) left ventricular pressure leaving unaltered coronary perfusion pressure, whereas DP7 did not affect both parameters. Nifedipine did not modify both QRS and QT intervals of electrocardiogram (ECG). Second-degree atrioventricular block or ventricular rhythm occurred in presence of nifedipine, however, in 4 out of 6 hearts. DP7, up to 30 microM, failed to alter ECG parameters. In conclusion, DP7, may represent a lead compound for the development of potent dihydropyridine MDR chemosensitizers devoid of cardiac effects.
Description: 
35339
URI: http://hdl.handle.net/20.500.12779/5304
ISSN: 0014-2999
DOI: 10.1016/j.ejphar.2007.02.001
Appears in Collections:Publications

Show full item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.